Biosciences
Our researchers in have a rich legacy of collaboration with government agencies and industry partners that improve health outcomes and well-being around the world. SRI Biosciences projects range from high-impact, early-stage research to drug co-development with pharmaceutical and biotech companies.
-
75 Years of Innovation: Twin Research Registry
The Twin Research Registry is a community registry of identical and fraternal twins to help in research into diseases, traits and behaviors
-
SRI International’s Parijat Bhatnagar receives DARPA award to continue groundbreaking research into engineered immunity
The prestigious award provides additional funds to continue developing cells that can be stimulated via extracorporeal devices to treat viral infections
-
SRI International enters drug discovery and research collaboration with Sanofi
Researchers will leverage SynFini, SRI’s artificial intelligence and automation platform, to accelerate development of small-molecule drug targets
-
Targeted Antigen Loaded Liposomes (TALL™)
SRI scientists exploit the human immune response to target cancer cells and extend the benefits of cancer immunotherapies. SRI’s Targeted Antigen Loaded Liposomes (TALL), a new immunotherapy with the potential to overcome these challenges and extend the benefits of immunotherapy to many more patients.
-
SRI International releases major update to its BioCyc family of websites
SRI International is pleased to announce a major update to the BioCyc family of websites. SRI’s BioCyc solution features a collection of nearly 18,000 Pathway/ Genome Databases (PGDBs) for sequenced bacteria and major eukaryotes and supporting software tools. BioCyc provides a reference on the genomes, metabolic pathways of thousands of sequenced organisms and the regulatory networks of some of the organisms. BioCyc data is obtained by combining computational inferences, import data from other databases, and…
-
SRI International receives IARPA contract for rapid, breath-based disease-detection system
SRI International has been awarded a contract under the Intelligence Advanced Research Projects Activity (IARPA) to evaluate whether a novel, prototype technology has the potential to detect COVID-19 and other infectious diseases through exhaled human breath. The rapid, noninvasive technology is designed to provide widespread disease screening in places such as malls, airports, stadiums, emergency…
-
DiaCyt™
First-in-class platform for delivery of biotherapeutics across the blood-brain barrier to the central nervous system The Problem The blood-brain barrier regulates the entry of molecules into the central nervous system (CNS). While necessary under normal physiology, this creates a significant challenge for drug discovery and therapeutic delivery for the treatment of neurodegenerative diseases such as…
-
Battling “COVID-Somnia”
Given this, how has the global community’s sleep been impacted by the current pandemic, which has all the makings for sleepless nights?
-
Expanding cancer immunotherapy by exploiting recall immunity – a new co-therapy option for checkpoint inhibitor
SRI International has developed a novel immunotherapy that is capable of delivering previously encountered antigenic peptides specifically to cancer cells and facilitating their presentation through the MHC class I pathway.
-
Immunology is coming to the rescue
SRI scientist explores how to tame and leverage the human immune system to prevent allergies and fight disease
-
SRI introduces DiaCyt™ CNS drug-delivery platform at 2021 JP Morgan Conference
Novel peptide-based technology delivers molecular cargo through the blood brain barrier, enabling CNS drug discovery and therapeutic delivery
-
The mental health impact of COVID-19 restrictions
How did pandemic isolation and pandemic-related changes affect individuals around the globe?